The pharmacological profile of auranofin, an orally active gold compound.
Auranofin (AF; ' Ridaura '), an oral chrysotherapeutic agent, parenteral gold sodium thiomalate (GST) and gold thioglucose (GTG) were evaluated in order to compare their preclinical profiles. AF was found to be more effective than GST and GTG in suppressing inflammation and stimulating cell-mediated immunity. In contrast to GST, AF inhibited cellular release of lysosomal enzymes, antibody-dependent cellular cytotoxicity, production of antibodies in adjuvant arthritic rats, and antibodies involved in cytotoxicity reactions. In pharmacokinetic studies, plasma gold in rats following AF administration, exhibited greater cell association than after GST administration. In conclusion, the pharmacological profile of AF is markedly different from those of GST and GTG and this suggests potential for improvements in chrysotherapy.
D000042:Absorption; D000284:Administration, Oral; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D000917:Antibody Formation; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006046:Gold / Q000031:analogs & derivatives* / Q000378:metabolism*; D006052:Gold Sodium Thiomalate / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D007249:Inflammation / Q000188:drug therapy; D007700:Kinetics; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D000893:Anti-Inflammatory Agents; D006052:Gold Sodium Thiomalate; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold